Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.

BACKGROUND & AIMS Treatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety. METHODS Patients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin. Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavirin dosage reduction (n = 249) or erythropoietin therapy (n = 251). RESULTS Rates of SVR were comparable between patients whose anemia was managed by ribavirin dosage reduction (71.5%) vs erythropoietin therapy (70.9%), regardless of the timing of the first intervention to manage anemia or the magnitude of ribavirin dosage reduction. There was a threshold for the effect on rate of SVR: patients who received <50% of the total milligrams of ribavirin assigned by the protocol had a significantly lower rate of SVR (P < .0001) than those who received ≥50%. Among patients who did not develop anemia, the rate of SVR was 40.1%. Eleven thromboembolic adverse events were reported in 9 of 295 patients who received erythropoietin, compared with 1 of 392 patients who did not receive erythropoietin. CONCLUSIONS Reduction of ribavirin dosage can be the primary approach for management of anemia in patients receiving peginterferon, ribavirin, and boceprevir for HCV infection. Reduction in ribavirin dosage throughout the course of triple therapy does not affect rates of SVR. However, it is important that the patient receives at least 50% of the total amount (milligrams) of ribavirin assigned by response-guided therapy. ClinicalTrials.gov number, NCT01023035.

[1]  M. Manns,et al.  Anemia during treatment with peginterferon Alfa‐2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial , 2013, Hepatology.

[2]  M. Ghany,et al.  An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.

[3]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[4]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[5]  Lai Wei,et al.  [Introduction and comments on EASL clinical practice guidelines: management of hepatitis C virus infection]. , 2011, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[6]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[7]  Stefan Zeuzem,et al.  Boceprevir for previously treated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[8]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[9]  E. Schiff,et al.  Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial , 2010, The Lancet.

[10]  L. Barbera,et al.  Erythropoiesis stimulating agents, thrombosis and cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  William M. Lee,et al.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.

[12]  V. Soriano,et al.  Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. , 2008, The Journal of antimicrobial chemotherapy.

[13]  P. Kwo,et al.  Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial , 2007, Hepatology.

[14]  William M. Lee,et al.  Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. , 2007, Gastroenterology.

[15]  M. Ichinose,et al.  Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C , 2005, Clinical and Experimental Medicine.

[16]  E. Schiff,et al.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. , 2004, Gastroenterology.

[17]  R. Gish,et al.  Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection , 2004, Journal of viral hepatitis.

[18]  E. Bini,et al.  Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. , 2003 .

[19]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[20]  P. Glue,et al.  The clinical pharmacology of ribavirin. , 1999, Seminars in liver disease.